Gilead Sciences and Genesis Therapeutics have formed a collaboration to develop novel therapies through generative AI technology. Genesis’ GEMS platform will assist in generating and optimizing molecules for targets selected by Gilead. Gilead holds exclusive rights to pursue clinical development and commercialization of resulting compounds.
Genesis’ AI platform addresses the challenge of limited training data for promising protein targets. By leveraging their expertise in generative AI, Genesis aims to accelerate drug discovery for complex targets. The collaboration combines Genesis’ AI capabilities with Gilead’s research and development experience.
Under the agreement, Genesis receives upfront payments and is eligible for milestones and royalties. The transaction is expected to impact Gilead’s financial measures, including EPS reduction.
Genesis Therapeutics utilizes AI to generate and optimize small molecule drug candidates. Their platform integrates proprietary AI techniques, such as language and diffusion models, and physical simulations. Genesis has raised significant funding to advance its AI-driven drug discovery efforts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
